BioSpace News Archive

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring, today announced the closing of its previously announced $11.0 million initial public offering of 1,226,668 units, each unit consisting of one share of common stock

Senseonics Holdings, Inc. announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.

The CDC “considers a person to have a fever when he or she has a measured temperature of 100.4° F (38° C) or greater.”

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2020 fiscal year, the period ended May 31, 2020, on Thursday, July 9, 2020.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), in

BioStem Technologies, Inc. (OTC PINK: BSEM), a leading life sciences company specializing in the development and commercialization of perinatal tissue-based allografts for regenerative therapies, today announced the submission of applications for three of its dehydrated placental membrane allograft products to the Centers for Medicare and Medicaid Services (CMS), in process to be granted Q-Codes. Q-Codes are established to identify drugs,

NGIO has previously developed Ii-Key-H1 peptides for vaccines against epitopes to 2009 Swine Flu and 2004 Bird Flu with positive Phase I clinical safety and immunologic data for Ii-Key-H1 peptide vaccine Ii-Key-H1 peptide sequence is 100% homologous in previous pandemic influenza threats Potential to launch Ii-Key-H1 peptide vaccine for emerging pandemic threat from G4 EA H1N1 swine flu Published reference: Honglei et al. Prevalent Eurasian Avian-like H1N1 Swine Influenza Virus with 2009 Pand

Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share. In addition, and in lieu of common stock, Neoleukin is offering to certain investors pre-funded warrants to purchase up to an aggre

California-based Fluxergy will work with Mass General Brigham (MGB), a major health system in Massachusetts, to further evaluate Fluxergy’s innovative Research Use Only (RUO) COVID-19 testing platform, designed to deliver accurate PCR test results in under one hour.